Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Testosterone for Middle-Aged and Older Men with Hypogonadism.

The New England journal of medicine·2025
Same author

Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis.

The New England journal of medicine·2025
Same author

Liraglutide for Children 6 to <12 Years of Age with Obesity.

The New England journal of medicine·2025
Same author

Cardiovascular Safety of Testosterone-Replacement Therapy.

The New England journal of medicine·2023
Same author

Once-Weekly Semaglutide in Adolescents with Obesity.

The New England journal of medicine·2023
Same author

Correction to: Safety and tolerability of high-dose daily vitamin D<sub>3</sub> supplementation in the vitamin D and type 2 diabetes (D2d) study-a randomized trial in persons with prediabetes.

European journal of clinical nutrition·2022
Same journal

PTPN2 gene polymorphisms are associated with type 1 diabetes mellitus in Brazilian subjects?

Arquivos brasileiros de endocrinologia e metabologia·2015
Same journal

PTPN2, a potential therapeutic target for type 1 diabetes?

Arquivos brasileiros de endocrinologia e metabologia·2015
Same journal

Response to the letter: Red cell distribution width in subclinical hypothyroidism.

Arquivos brasileiros de endocrinologia e metabologia·2015
Same journal

Red cell distribution width in subclinical hypothyroidism.

Arquivos brasileiros de endocrinologia e metabologia·2015
Same journal

Response to the letter: Angiotensin-II induced insulin resistance.

Arquivos brasileiros de endocrinologia e metabologia·2015
Same journal

Angiotensin-II induced insulin resistance.

Arquivos brasileiros de endocrinologia e metabologia·2015
See all related articles

Related Experiment Video

Updated: May 26, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Biosimilars.

Saul Malozowski1

  • 1National Institutes of Health, NIDDK, USA. malozowskis@extra.niddk.nih.gov

Arquivos Brasileiros De Endocrinologia E Metabologia
|January 6, 2012
PubMed
Summary
This summary is machine-generated.

Regulatory policies for biologics are evolving globally, requiring adaptable frameworks. Agencies, industry, and the public must collaborate for realistic expectations and efficient drug approval processes.

More Related Videos

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Related Experiment Videos

Last Updated: May 26, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Area of Science:

  • Biopharmaceutical regulatory affairs
  • Global health policy

Background:

  • International regulatory policies for biologics exhibit common themes but also significant divergences.
  • Existing and developing policies face challenges in accommodating diverse biologics and emerging scientific advancements.

Purpose of the Study:

  • To analyze the dynamic nature of global regulatory policies for biologics.
  • To identify areas for improved collaboration between regulatory agencies, the pharmaceutical industry, and the public.

Main Methods:

  • Review of current international regulatory landscapes for biologics.
  • Analysis of policy adaptability to novel and complex biological products.

Main Results:

  • Policies are in flux and not universally applicable to all biologics.
  • Accelerated approval pathways should be considered for less complex compounds.
  • A need exists for greater transparency from regulatory agencies and social responsibility from industry.

Conclusions:

  • Regulatory frameworks for biologics require continuous adaptation to scientific progress.
  • Enhanced collaboration and realistic public expectations are crucial for effective biologic development and approval.